Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?
作者信息
Spellberg Brad, Bonomo Robert A
机构信息
Division of Infectious Diseases, Keck School of Medicine at USC and the Los Angeles County-USC Medical Center, Los Angeles, CA Department of Medicine, Department of Pharmacology, Department of Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH.
出版信息
Crit Care Med. 2015 Jun;43(6):1332-4. doi: 10.1097/CCM.0000000000001029.
Abstract
摘要
相似文献
1
Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?针对广泛耐药鲍曼不动杆菌的联合治疗：时机已成熟？
Crit Care Med. 2015 Jun;43(6):1332-4. doi: 10.1097/CCM.0000000000001029.
2
"Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia.“超额死亡率”与多黏菌素-替加环素治疗广泛耐药鲍曼不动杆菌血症
Crit Care Med. 2015 Oct;43(10):e470-1. doi: 10.1097/CCM.0000000000001152.
3
Appropriate Tigecycline Use for Extensively Drug-Resistant Infections: The Standard Dose May Not Be Enough!替加环素用于广泛耐药感染的合理应用：标准剂量可能不足！
Crit Care Med. 2015 Nov;43(11):e533-4. doi: 10.1097/CCM.0000000000001230.
4
Mortality and Extensively Drug Resistance: Drugs or Methods? That Is the Question!死亡率与广泛耐药性：药物还是方法？这才是问题所在！
Crit Care Med. 2015 Nov;43(11):e538. doi: 10.1097/CCM.0000000000001240.
5
Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.与多黏菌素-替加环素相比，多黏菌素-碳青霉烯类联合疗法治疗广泛耐药鲍曼不动杆菌血症的额外死亡率：一项多中心前瞻性观察研究
Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.
6
In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.黏菌素、替加环素和多尼培南抗生素组合对广泛耐药和多重耐药鲍曼不动杆菌的体外相互作用
Ann Lab Med. 2016 Mar;36(2):124-30. doi: 10.3343/alm.2016.36.2.124.
7
Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.多黏菌素联合治疗广泛耐药鲍曼不动杆菌肺炎。
Int J Antimicrob Agents. 2014 Apr;43(4):378-82. doi: 10.1016/j.ijantimicag.2014.01.016. Epub 2014 Feb 14.
8
Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain.西班牙发生产OXA-23碳青霉烯酶的多重耐药鲍曼不动杆菌医院感染暴发。
Microb Drug Resist. 2014 Aug;20(4):259-63. doi: 10.1089/mdr.2013.0127. Epub 2013 Dec 11.
9
Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.多黏菌素-替加环素与多黏菌素-亚胺培南-西司他丁联合用药治疗鲍曼不动杆菌呼吸机相关性肺炎的预后研究
Intensive Care Med. 2015 Nov;41(11):2018-9. doi: 10.1007/s00134-015-4010-z. Epub 2015 Aug 12.
10
Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.碳青霉烯类耐药鲍曼不动杆菌菌血症患者死亡的危险因素。
J Microbiol Immunol Infect. 2016 Dec;49(6):934-940. doi: 10.1016/j.jmii.2014.10.006. Epub 2014 Nov 11.
引用本文的文献
1
Antibiotic-potentiating efficacy of L. to combat planktonic cells, biofilms, and efflux pump activities of extensively drug-resistant clinical strains.乳酸杆菌对抗浮游细胞、生物膜以及广泛耐药临床菌株外排泵活性的抗生素增效功效。
Front Pharmacol. 2025 Apr 8;16:1558611. doi: 10.3389/fphar.2025.1558611. eCollection 2025.
2
Carbapenem-induced β-lactamase-isoform expression trends in Acinetobacter baumannii.碳青霉烯类抗生素诱导鲍曼不动杆菌β-内酰胺酶亚型表达趋势
Sci Rep. 2024 Dec 28;14(1):30841. doi: 10.1038/s41598-024-81501-z.
3
Synergistic effects of bacteriophage cocktail and antibiotics combinations against extensively drug-resistant Acinetobacter baumannii.噬菌体鸡尾酒与抗生素联合应用对广泛耐药鲍曼不动杆菌的协同作用。
BMC Infect Dis. 2024 Oct 26;24(1):1208. doi: 10.1186/s12879-024-10081-0.
4
A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles.综述鲍曼不动杆菌的三种对抗策略：抗生素、噬菌体和纳米颗粒。
Mol Biol Rep. 2024 Oct 8;51(1):1044. doi: 10.1007/s11033-024-09979-4.
5
Comparison of Hypervirulent and Non-Hypervirulent Carbapenem-Resistant Isolated from Bloodstream Infections: Mortality, Potential Virulence Factors, and Combination Therapy In Vitro.血流感染中分离出的高毒力和非高毒力耐碳青霉烯菌的比较：死亡率、潜在毒力因子及体外联合治疗
Antibiotics (Basel). 2024 Aug 26;13(9):807. doi: 10.3390/antibiotics13090807.
6
A novel multivariate logistic model for predicting risk factors of failed treatment with carbapenem-resistant ventilator-associated pneumonia.一种用于预测碳青霉烯类耐药呼吸机相关性肺炎治疗失败风险因素的新型多变量逻辑模型。
Front Public Health. 2024 May 9;12:1385118. doi: 10.3389/fpubh.2024.1385118. eCollection 2024.
7
Characterization of antibiotic and disinfectant susceptibility in biofilm-forming Acinetobacter baumannii: A focus on environmental isolates.生物膜形成鲍曼不动杆菌对抗生素和消毒剂的敏感性特征：聚焦于环境分离株
Eur J Microbiol Immunol (Bp). 2024 Mar 5;14(2):126-133. doi: 10.1556/1886.2024.00014. Print 2024 May 14.
8
Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects.SPR206 在健康成年受试者静脉给药后的血浆、肺上皮衬液和肺泡巨噬细胞中的药代动力学。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0042623. doi: 10.1128/aac.00426-23. Epub 2023 Jun 20.
9
A novel strategy to characterize the pattern of β-lactam antibiotic-induced drug resistance in Acinetobacter baumannii.一种鉴定鲍曼不动杆菌β-内酰胺类抗生素诱导耐药模式的新策略。
Sci Rep. 2023 Jun 6;13(1):9177. doi: 10.1038/s41598-023-36475-9.
10
A novel strategy to characterize the pattern of β-lactam antibiotic-induced drug resistance in Acinetobacter baumannii.一种表征鲍曼不动杆菌中β-内酰胺类抗生素诱导的耐药模式的新策略。
Res Sq. 2023 Jan 19:rs.3.rs-2359505. doi: 10.21203/rs.3.rs-2359505/v1.
本文引用的文献
1
Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.与多黏菌素-替加环素相比，多黏菌素-碳青霉烯类联合疗法治疗广泛耐药鲍曼不动杆菌血症的额外死亡率：一项多中心前瞻性观察研究
Crit Care Med. 2015 Jun;43(6):1194-204. doi: 10.1097/CCM.0000000000000933.
2
Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.碳青霉烯类耐药鲍曼不动杆菌菌血症患者死亡的危险因素。
J Microbiol Immunol Infect. 2016 Dec;49(6):934-940. doi: 10.1016/j.jmii.2014.10.006. Epub 2014 Nov 11.
3
A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.一项病例对照研究，旨在确定碳青霉烯类耐药鲍曼不动杆菌菌血症 14 天死亡率的预测因素。
Clin Microbiol Infect. 2014 Dec;20(12):O1028-34. doi: 10.1111/1469-0691.12716. Epub 2014 Aug 11.
4
Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii.比较多黏菌素和替加环素对广泛耐药鲍曼不动杆菌的疗效和安全性。
Biol Pharm Bull. 2014;37(3):340-6. doi: 10.1248/bpb.b13-00109.
5
Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.在重症环境下，基于替加环素与基于黏菌素的治疗方案对多重耐药鲍曼不动杆菌所致肺炎的治疗效果：一项配对队列分析
BMC Infect Dis. 2014 Feb 24;14:102. doi: 10.1186/1471-2334-14-102.
6
Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia.鲍曼不动杆菌血症患者死亡的危险因素
Infect Chemother. 2013 Sep;45(3):325-30. doi: 10.3947/ic.2013.45.3.325. Epub 2013 Sep 27.
7
Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.危重症患者鲍曼不动杆菌血流感染的危险因素及转归分析。
Crit Care Med. 2014 May;42(5):1081-8. doi: 10.1097/CCM.0000000000000125.
8
The value of single-pathogen antibacterial agents.单病原菌抗菌药物的价值。
Nat Rev Drug Discov. 2013 Dec;12(12):963. doi: 10.1038/nrd3957-c1. Epub 2013 Nov 15.
9
Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.碳青霉烯类耐药的鲍曼不动杆菌感染患者的耐药性和死亡率：系统评价和荟萃分析。
Clin Microbiol Infect. 2014 May;20(5):416-23. doi: 10.1111/1469-0691.12363. Epub 2013 Oct 17.
10
The FDA reboot of antibiotic development.美国食品药品监督管理局重启抗生素研发。
Antimicrob Agents Chemother. 2013 Oct;57(10):4605-7. doi: 10.1128/AAC.01277-13. Epub 2013 Jul 29.
Zotero 插件